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Abstract
Candida endocarditis is a life-threatening, opportunistic fungal infection of the
endocardium. The mortality rate of Candida endocarditis is approximately 50% and
has been increasing in incidence over recent years. Historically, amphotericin B and
flucytosine has been considered the standard of treatment for candida endocarditis,
but is limited by safety concerns of amphotericin B, primarily nephrotoxicity and
hepatotoxicity. Echinocandins, such as micafungin, have demonstrated similar
efficacy in other forms of invasive candidiasis with better safety profiles, but there
have been no large-scale or direct comparison trials. In this review, we summarize
existing data between micafungin, an echinocandin, vs. amphotericin B and
flucytosine in the setting of candida endocarditis. The information extrapolated will
determine if micafungin is an appropriate comparator to amphotericin B and
flucytosine for the primary treatment of candida endocarditis.
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Chapter 1 – Introduction
1.1 Background
Fungal infective endocarditis is now increasing in incidence due to a growing
number of at-risk patients, which include intravenous drug users and
immunocompromised individuals.1,2 Worldwide, the prevalence rate of infective
endocarditis in 2016 was 6.7 per 100,000 persons, with an incidence rate of 15.8 per
100,000 persons.3 Approximately 2-4% of these cases are fungal infective
endocarditis, primarily through complications of fungaemia, which, in recent years,
has increased by 128%.2,4 The most common causative agent, Candida albicans,
manifests within three subsets of endocarditis: native valve endocarditis, prosthetic
valve endocarditis, and cardiac-device related endocarditis.1,5 Current guidelines
endorsed by the Infectious Diseases Society of America (IDSA) recommend that
these subsets of endocarditis be treated with surgical replacement of the infected
valves and/or cardiac devices;1 however, two separate meta-analyses performed by
the International Collaboration of Endocarditis-Prospective Cohort Study showed that
among a cohort study of seventy cases, mortality rates between medical therapy alone
and adjunctive surgical therapy after medical therapy were similar.4,6 In conjunction
with this data provided by the two largest prospective studies of Candida infective
endocarditis, not all patients are eligible for surgical intervention due to a myriad of
reasons, which elicits an outstanding need for standardized, effective pharmacologic
management.4,6
In regard to current pharmacologic guidelines, the IDSA recommends that
patients are initially started on either lipid formulations of amphotericin B, with or
without flucytosine, or a high-dose echinocandin (i.e. caspofungin 150 mg daily,
1

micafungin 150 mg daily, or anidulafungin 200 mg daily).4,7 Upon clearance of
fungaemia, step-down therapy to an azole is recommended after susceptibility testing,
followed by valve and/or cardiac device replacement; however, in the instance of
surgical contraindications, fluconazole is also used as the main agent for long-term
suppression therapy.4 Yet, despite following these recommendations, mortality for
patients have been estimated to be as high as 80% in published cases, prompting a
need for a more comprehensive understanding of the disease and its treatment
modalities.4,8
Amphotericin B had historically been the standard of care for several
opportunistic fungal infections including invasive candidiasis, cryptococcal
meningitis, and aspergillosis.9 It was the first broad antifungal agent developed for
treating such diseases through its ability to bind to ergosterol in the fungal cell
membrane, leading to the formation of pores, ion leakage, and, ultimately, fungal cell
death.9 Although demonstrating an ability to target most Candida strains, except for
Candida lusitaniae, amphotericin B not only has been known to produce common and
severe toxicities, but also has been ineffective at penetrating into fibrin clots and
vegetations associated with Candida endocarditis biofilms.1,7 Furthermore, antifungal
monotherapy, specifically with amphotericin B, without adjunctive surgery has been
associated with the poorest patient outcomes when compared to medical antifungal
combination therapy with or without adjunctive surgery.1 However, with liposomal
formulations of amphotericin B, which is comprised of hydrogenated soy
phosphatidylcholine, distearoyl phosphatidylglycerol, and cholesterol, this agent has
shown an ability to maintain its antifungal properties by penetrating the extracellular
membrane to target fungal cells, as well as reducing dose-limiting toxicities
2

associated with amphotericin B, most markedly nephrotoxicity, infusion-related
reactions, and hepatotoxicity.9 Additionally, the liposomal formulation of
amphotericin B, compared to amphotericin B deoxycholate, has demonstrated better
abilities at addressing the issues associated with the development of biofilms.9
Additionally, flucytosine, another antifungal agent, is commonly given in
combination with other antifungal agents, most commonly amphotericin B while
treating refractory Candida infections, including Candida endocarditis and
endophthalmitis.7 Current literature suggests that positive clinical outcomes are more
associated with combination antifungal therapy of amphotericin B and flucytosine
compared to antifungal monotherapy of either amphotericin B or flucytosine.1 In fact,
flucytosine monotherapy has been shown to rapidly produce drug-resistant strains of
Candida.1 The success from this combination therapy stems from the synergistic
antifungal effects provided through the addition of flucytosine, which, has
demonstrated broad antifungal activity against most Candida species, except for
Candida krusei.1,7
While this combination therapy has shown promising clinical results, the
ability of these antifungal agents to penetrate biofilms of Candida species other than
Candida albicans is poor compared to the abilities of the echinocandins.10
Echinocandins are a newer class of antifungal agents that block the production of 1,3β-D-glucan, which is an essential component of the fungal cell wall, and have
demonstrated their activity against almost all strains of Candida species.7 Each of the
three existent echinocandins, micafungin, caspofungin, and anidulafungin, has
demonstrated efficacy in the treatment of invasive candidiasis.7 In addition to several
case reports and case series that demonstrate the efficacy of echinocandins in treating
3

Candida endocarditis, there have been in vitro studies that have also shown successful
elimination of model Candida biofilms that mimic vegetations residing in the
endocardium.1,6,10 The importance of penetrating these biofilms is clinically
significant because the biofilms are associated with drug resistance, which ultimately
lead to treatment failure.10 Through eradication of the biofilms in the heart or affected
intravascular devices, it may be possible for Candida endocarditis to be treated
without the need for adjuvant surgery, which would possibly allow for preservation of
the infected intravascular devices and/or remove the necessity for valve surgery in the
setting of Candida endocarditis.10
Another benefit of this class of medication is its safety—compared to
liposomal amphotericin B, the echinocandins have fewer adverse effects, most
notably lacking nephrotoxicity.7 Since echinocandins primary route of elimination
from the body is through nonenzymatic degradation, they do not require dosage
adjustments for patients with renal insufficiency or dialysis;7 however, caspofungin
and micafungin undergo minimal hepatic metabolism, with only caspofungin having
dosage reduction recommendations for patients with moderate to severe hepatic
insufficiency.7
Current treatment recommendations supported by the IDSA are based off of a
meta-analysis of currently available literature; however, the evidence for their
recommendations are derived only from case reports and case series.1 There have
been no prospective or randomized trials performed that compare amphotericin B
combination therapy to echinocandin-based therapy in the setting of Candida
endocarditis.1,6 With such scarce clinical data within this realm of invasive fungal
disease, a prospective, randomized, double-blind, international multi-centre, non4

inferiority trial is proposed to compare the efficacy and safety between liposomal
amphotericin B with flucytosine and high-dose micafungin for the primary treatment
of Candida endocarditis. Since amphotericin B with flucytosine is limited in its use
through adverse events, micafungin would provide an appropriate alternative therapy
in the primary treatment of Candida endocarditis.
1.2 Problem Statement
Current recommendations endorsed by the ISDA for the primary treatment of
Candida endocarditis is either liposomal amphotericin B, with or without flucytosine,
or a high-dose echinocandin;7 however, there are currently no clinical data or trials
comparing the efficacy of these recommendations.6 Amphotericin B-based therapy
has long been considered the gold standard of treatment for Candida endocarditis due
to its historical use and multiple cases of documented success, but remains
cumbersome in its use due to its nephrotoxicity, even after the development of its less
nephrotoxic liposomal formulation.6 However, with an attractive safety profile, in
vitro studies demonstrating success against Candida biofilm models, and comparison
studies revealing non-inferiority to the amphotericin B-based therapy in the setting of
candidemia, echinocandins show potential of being an alternative primary treatment
for Candida endocarditis.6 The absence of prospective, randomized control trials
warrants a study to determine the safety and efficacy between these two treatments in
the setting of Candida endocarditis.
1.3 Goals and Objectives
The proposed study aims to determine if micafungin would be an appropriate
primary alternative pharmacologic treatment to liposomal amphotericin B with
flucytosine in the setting of Candida endocarditis. The goal of this study will be to
5

evaluate the outcomes between micafungin-based therapy and liposomal amphotericin
B-based therapy for the primary treatment of Candida endocarditis by (i) determining
non-inferiority of all-cause mortality from initiation of medication to day fifty-six, (ii)
measuring time to clearance of candidemia, (iii) assessing safety through drug-related
adverse effects, and (iv) quantifying the incidence of relapse following initiation of
maintenance therapy.
The primary study outcome, all-cause mortality from initiation of medication
to day fifty-six of treatment, will be used to determine non-inferiority between the two
proposed pharmacological regimens. The secondary outcomes will consist of
measuring time to clearance of candidemia, assessing the safety profile through
adverse side effects, and identifying the incidence of Candida endocarditis relapse
after the initiation of step-down maintenance therapy. The information collected
through the secondary outcomes will allow for a better understanding of optimal
dosing for the two antifungal regimens.
1.4 Hypothesis
We hypothesize that micafungin will be non-inferior in all-cause mortality to
day fifty-six in the treatment of Candida endocarditis when compared to liposomal
amphotericin B with flucytosine.
1.5 Definitions
Infective endocarditis was defined according to the modified Duke criteria.11
Probable and proven Candida endocarditis were defined according to both the
modified Duke Criteria and EORTC/MSG.5,12 Candida endocarditis-related death was
defined as the patient having signs of endocarditis at the time of death, meaning
6

positive blood cultures for Candida species and/or one other major criterion, or three
minor criteria per the modified Duke criteria.11,13
Table 1. Definition of Candida Endocarditis per Modified Duke Criteria
Proven Candida Endocarditis
Pathologic criteria:
1. Candida species demonstrated
by culture or histologic
examination of a vegetation,
embolized vegetation, or
intracardiac abscess specimen; or
2. Pathologic lesions—vegetation
or intracardiac abscess
confirmed by histologic
examination showing active
endocarditis
Clinical criteria:
1. 2 major criteria; or
2. 1 major criterion and 3 minor
criteria; or
3. 5 minor criteria

Probable Candida Endocarditis
1. 1 major and 1 minor criterion; or

2. 3 minor criteria

11,14,15

Table 2. Major and Minor Criteria in the Modified Duke Criteria
Major Criteria
1. Persistently positive blood
cultures:
a. ≥2 positive blood
cultures of blood samples
drawn >12h apart; or
b. ≥3 or >4 separate
cultures of blood with
first and last samples
drawn at least 1h apart
2. Evidence of endocardial
involvement:
a. Echocardiography
positive for infective
endocarditis
b. New valvular
regurgitation

Minor Criteria
1. Predisposing lesion or IV
drug use

2. Fever >38.0°C

3. Vascular phenomena—major
arterial emboli, septic
pulmonary infarcts, etc.
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4. Immunologic phenomena—
glomerulonephritis, Roth’s
spots, etc.
5. Microbiological evidence—
positive blood cultures not
meeting major criterion or
serologic evidence of an
active infection with an
organism known to cause
infective endocarditis
6. Echocardiographic findings
consistent with infective
endocarditis, but do not meet
major criteria
11,14,15

Probable and proven candidemia were defined according to the criteria set by
the European Organization for Research and Treatment of Cancer/Invasive Fungal
Infections Cooperative Group and the National Institute of Allergy and Infectious
Diseases Mycoses Study Group (EORTC/MSG).12 Time to clearance of candidemia
was defined as having demonstrated clinical stability and clearing Candida from the
bloodstream with initiation of maintenance azole therapy.7 Candida endocarditis
relapse was defined as a new episode of endocarditis due to the same Candida species
in patients that completed their assigned IV treatment and achieved time to clearance
of candidemia.13
Table 3. Definitions for Invasive Candida Infections
Category
Proven Candidemia

Probable Candidemia

Definition
Proof of invasive Candida disease by demonstration of
Candida-specific elements in diseased tissue of most
conditions
Host factor, clinical features, and evidence of Candida are
present

12,16
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The safety profiles of each study regimen were defined according to the
Patient-Reported Outcomes Version of the Common Terminology Criteria for
Adverse Events (PRO-CTCAE).17-19
Table 4. Grades from Common Terminology Criteria for Adverse Events
Grades

Definition

Grade 1

Mild; asymptomatic or mild symptoms; clinical or diagnostic
observations only; intervention not indicated

Grade 2

Moderate; minimal, local, or non-invasive intervention indicated;
limiting age-appropriate instrumental activities of daily living

Grade 3

Severe or medically significant, but not immediately life-threatening;
hospitalization or prolongation of hospitalization indicated; disabling;
limiting self-care activities of daily living

Grade 4

Life-threatening consequences; urgent indication indicated

Grade 5

Death related to adverse events

17-19
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Chapter 2 – Review of the Literature
2.1 Introduction
A thorough review of the literature was conducted between December 2019 to
April 2020 using Ovid (Medline, Embase) and Pubmed. Limitations were placed on
publication year with the use of each database to only include studies from the last
five years. Publications cited within these articles that did not fall within the time
limitations were also considered for inclusion in the current analysis. Additionally,
only articles written and/or translated into English were reviewed. Duplicated
versions of articles were removed as well. Titles and abstracts were then reviewed to
determine relevance to our proposed study.
Articles and cases were included in the current analysis if they met the
following inclusion criteria: (i) met criteria for proven or probable Candida
endocarditis, (ii) used an echinocandin-based therapy or a liposomal amphotericin Bbased therapy, and (iii) contained specific information about the outcome of the
patient(s). Articles and cases were excluded if they (i) received concurrent
amphotericin B-based and echinocandin-based therapy, (ii) received less than seven
days of systemic antifungal therapy, or (iii) received surgical intervention only.
The key terms that were utilized include Candida, endocarditis, amphotericin
B, micafungin, and echinocandin. Of the 141 articles, 38 were fully reviewed to be
included within the literature review. The purpose of this literature review is to justify
the protocol-specific determinations of our study.
2.2 Overview of Candida Endocarditis
Fungal endocarditis has an alarmingly high mortality ranging from 30-80%,
with 53-68% of all cases being Candida species, affecting primarily neutropenic and
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critically ill, non-neutropenic patients, especially in the nosocomial setting.1-8
Candida albicans has been identified as being the most common species causing
candidemia and Candida endocarditis.2,6-8 Prior to 1980, mortality rates for Candida
endocarditis were reported to be as high as 80%, but through advancements of
antifungal agents and cardiac surgeries, mortality rates have fallen from 46% to 30%
within the last decade.3
Risk factors for the development of Candida endocarditis include not only all
variables that predispose patients to candidemia—central venous catheters, parenteral
nutrition, immunosuppression, and prior surgical procedures, but also ones that
predispose patients to endocarditis, such as intravenous drug use/abuse, prosthetic
heart valves, valvular abnormalities, transcatheter aortic valve replacement,
congenital heart abnormalities, previous endocarditis infections, and
pacemaker/cardiac defibrillator placement.3,4,6,7,9 Out of all of these risk factors, the
one that poses the highest threat to the development of Candida endocarditis is the
presence of prosthetic heart valves, which is increasing due to the utilization of
transcatheter aortic valve replacement and an aging population.3,9 The valves that are
most affected are typically the aortic valve, followed by the mitral valve.3,5 Based on
these risk factors, it is predicted that the incidence of Candida endocarditis will
increase due to the increasing number of elderly patients worldwide, increasing
number of immunocompromised patients worldwide, and increasing frequency of
intravascular device placement.5,7
The clinical presentation of Candida endocarditis is a combination of the signs
and symptoms associated with candidemia, infectious endocarditis, and
coagulopathies associated with endocarditis.3,4,6,10 The presence of a new or changing
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murmur in conjunction with the development of large vegetations with proceeding
venous thromboembolic events are cardinal findings of Candida endocarditis.3,6,10
Candida endocarditis should be highly suspected in patients with multiple
blood cultures positive for Candida species and a major venous thromboembolic
event; however, it should be noted that not every blood culture will be positive for
Candida species in the setting of candidemia due to their nature of being slowgrowing, obligate aerobes and the sensitivity for detection being between 5075%.3,4,6,7 Additionally, the use of transthoracic echocardiography and/or
transoesophageal echocardiography is an extremely useful tool in making the
diagnosis of Candida endocarditis, especially in occult infections, through their ability
to identify vegetations in the heart.3,6,10 Although both types of echocardiography are
sufficient evidence for the diagnosis of Candida endocarditis, only the use of
transoesophageal echocardiography can reasonably exclude the diagnosis of Candida
endocarditis due to its increased sensitivity and specificity compared to transthoracic
echocardiography.6,10
In addition to causing significant fungal infections, C. albicans is known for
being extremely difficult to treat clinically due to its ability to create biofilms.9,11,12
These biofilms promote resistance to conventional antifungal therapies, at times,
leading to clinical failure.9,11-13 Echinocandins and liposomal amphotericin B have
been identified as the most effective therapy against biofilms, but there has been
evidence of in vivo development of resistance to these novel antifungals.9,11,12 Azoles,
which include fluconazole, voriconazole, itraconazole, and posaconazole, were
initially thought to be a safe and effective therapy in the treatment of Candida
endocarditis, but data showed that there was a high frequency for failure and relapse,
resulting in a discontinuation of this treatment standard.3,14 Instead, it was discovered
14

that the most effective use of these medications was after clearance of candidemia and
subsequent susceptibility testing of the Candida species. 4,6,13,15-17 These medications
are better served in the step-down therapy of maintaining remission for Candida
endocarditis because of their fungistatic properties.4,6,13,15-17
2.3 Current Treatment Guidelines
Guidelines in the treatment of Candida endocarditis written by both the IDSA
and European Society of Microbiology and Clinical Infectious Diseases (ESCMID)
now recommend either an amphotericin B-based or an echinocandin-based therapy
paired with adjunctive surgery.6,15,18 These recommendations specifically indicate
either liposomal amphotericin B (3-5 mg/kg daily IV), with or without flucytosine (25
mg/kg QID PO), or a high-dose echinocandin (caspofungin 150 mg daily IV,
micafungin 150 mg daily IV, or anidulafungin 200 mg daily IV).15 Antifungal therapy
should be administered for six to eight weeks, but not less than four weeks.6
Due to the high mortality rates and poor prognosis of patients that are treated
with medical treatment alone, fungal endocarditis is considered an indication for
cardiac surgery and/or valve replacement.5,6,18 However, these guidelines are based on
evidence provided only by case reports, case series, and clinical experience since
there are no randomised control trials exploring the most effective treatment strategy
for this infectious disease.18 Additionally, in cases where cardiac surgery is not an
option, it is unknown what the optimal primary medical management would be for
Candida endocarditis.2 This gap in the literature has even been noted by the IDSA,
acknowledging that their current guidelines are based on low-quality evidence.15
To date, there have only been observational studies that compare the efficacy
of an amphotericin B-based therapy to an echinocandin-based therapy for Candida
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endocarditis.18 Furthermore, there have been no prospective, randomised trials
comparing the efficacy of an amphotericin B-based therapy to an echinocandin-based
therapy in the primary treatment of Candida endocarditis.4,18
A retrospective study conducted by Steinbach et al. found that survival
likelihood increased with the use of surgery and an antifungal therapy compared to
antifungal therapy alone.2 However, a prospective study conducted by Baddley et al.
had data showing that mortality rates were similar between patients receiving either
surgery and an antifungal therapy (33.3%) or antifungal therapy alone (27.8%)
(p=0.26).19 Additionally, there have been a number of studies that demonstrate
treatment success with novel antifungal agents, such as echinocandins, in medical
therapy alone.4 Surgical management of Candida endocarditis has been linked to a
high incidence of venous thromboembolic events, such as embolic haemorrhagic or
ischaemic stroke.4 These complications have been involved in 60% of cases.4
2.4 Liposomal Amphotericin B
Prior to the development of further classes of antifungal agents, the standardof-care treatment for life-threatening systemic fungal infections caused by species of
Candida, Aspergillus, and Fusarium has been an amphotericin B-based regimen,
which is part of a class of antifungals known as polyenes.4,17,18,20 The polyene
structure of amphotericin B forms complexes with ergosterol, which is an essential
component of fungal membranes, interrupting the integrity of the cell membrane and
causing leakage of essential cellular components.20,21
In instances where adjunctive surgery is not an option, patients would receive
extended courses of amphotericin B deoxycholate, which has been associated with a
high mortality rate and amphotericin B-induced nephrotoxicity.2,4,14,17,20 Because of
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these dose-dependent side effects, a need for formulations that reduce toxicity and
transport the agent efficiently to specific locations, while still maintaining its
antifungal effects arose.20 This led to the creation of three additional formulations of
amphotericin B—liposomes, emulsions, and nanoparticles.20
Most medical centres are currently using lipid-based amphotericin B
formulations, more specifically, liposomal amphotericin B, which has a narrower
toxicity profile when compared to amphotericin B deoxycholate.3,14,20 It has been
postulated that the reason liposomal amphotericin B is less nephrotoxic is due to the
drug’s large molecular size and neutral charge, resulting in a more rapid and specific
distribution to tissues and organs with large reticuloendothelial composition (i.e. liver,
spleen, lungs, lymphatics), which spares the kidneys, allowing increased deliverance
of amphotericin B to certain sites of infection.15,21
Flucytosine is commonly paired with liposomal amphotericin B because it
provides synergistic fungicidal effects, but if used in high doses or for an extended
time period, there is a risk for bone marrow toxicity.3,4 Additionally, similar to
liposomal amphotericin B, flucytosine requires dosage adjustments for patients with
renal insufficiency.15
2.5 Clinical Implications of Echinocandins
With developments in antifungal therapy, a new class of medications,
echinocandins, created an increase in options for the treatment of Candida
endocarditis.17,18,22 Echinocandins have shown a decrease in mortality rate compared
to other antifungal agents when used in the setting of candidemia and other invasive
Candida infections.23 A panel of experts from the United States of America, Middle
East region, and Italy have stated in their recommendations that echinocandins are the
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preferred treatment of proven or probable candidemia, especially in the setting of
critically ill patients or patients with previous exposure to azoles.1,10,23 Furthermore,
first-line treatment guidelines of Candida endocarditis in United Kingdom have
shifted towards high-dose echinocandins instead of liposomal amphotericin B.10,24
Echinocandins not only have the benefit of being active against a broad
spectrum of Candida species, but they also have a low tendency to cause drug-drug
interactions and contain a less severe adverse effect profile.4,9,10,13,14,16,17,22,25
Echinocandins implement their fungicidal capabilities through their ability to inhibit
beta-glucan synthesis, thus disrupting the integrity of the fungal cell wall.13,17,18 With
the disruption of cell wall integrity, intracellular osmotic pressure becomes unstable,
causing fungal cell lysis.26 The absence of cell walls in mammalian cells is thought to
be a contributing factor to their attractive safety profile.14,17,26 The improved
tolerability of these antifungals allows for prolonged, high-dose treatments when
necessary.4,24
The first echinocandin approved for the treatment of invasive candidiasis was
caspofungin in 2003, followed by micafungin and anidulafungin in 2005 and 2006,
respectively.18,26 Unfortunately, echinocandins cannot be used to treat all types of
Candida infections because they do not have the ability to reach therapeutic
concentrations for infections of the eyes, central nervous system, and urine.15
2.6 Echinocandin Therapy Success in Candidemia
A prospective, double-blind, randomised control trial was conducted in
patients with candidemia (n=244) to evaluate non-inferiority between treatment with
caspofungin (n=109) or amphotericin B (n=115).17 Duration of treatment between the
two groups was similar (p=0.60) with the caspofungin group having a mean treatment
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length of 12.1 days (median 11.0 days) and amphotericin B having a mean treatment
length of 11.7 days (median 10.0 days).17
In the modified intention-to-treat analysis, it was noted that the 12.7%
difference in proportion for treatment efficacy amongst non-neutropenic patients was
without statistical significance between the caspofungin group (73.4%) and the
amphotericin B group (61.7%) (95.6% CI, -0.7-26.0; p=0.09).17 Additionally, relapse
rates of candidemia were similar between the caspofungin group (6.4%) and the
amphotericin B group (7.0%).17 However, when evaluating the successful outcomes
among patients that met prespecified criteria for evaluation, which were patients
within the modified intention-to-treat population in conjunction with no concomitant
antifungal therapies, no protocol violations, an appropriate evaluation at the end of
treatment, and receipt of study treatment for at least five days, the caspofungin group
was favoured (80.7%) over the amphotericin B group (64.9%), with a statistically
significant difference of 15.4% (95.6% CI, 1.1-29.7; p=0.03).17
Through evaluation of safety and tolerability, it was noted that all drug-related
adverse events of statistical significance demonstrated favourability of caspofungin.17
Overall, the caspofungin group had a statistically significant lower proportion of
clinical events (28.9%, vs 58.4% in the amphotericin B group; p=0.002).17 Patients
receiving amphotericin B had a higher rate of experiencing chills (26.4%, vs. 5.3% in
the caspofungin group; p=0.003) and fever (23.2%, vs. 7.0% in the caspofungin
group; p=0.01).17 Furthermore, amphotericin B had a statistically larger proportion of
laboratory abnormalities (54.0%, vs. 24.3% in the caspofungin group; p=0.002),
including elevated blood urea nitrogen (15.8%, vs. 1.9% in the caspofungin group;
p=0.02), elevated serum creatinine (22.6%, vs. 3.7% in the caspofungin group;
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p=0.05), and decreased serum potassium (23.4%, vs. 9.9% in the caspofungin group;
p=0.04).17
Due to the number of adverse effects experienced by the patients in this study,
it should be noted that the amphotericin B group had a larger proportion of patients
that experienced toxic effects (16.5%, vs. 2.8% in the caspofungin group; p=0.03),
resulting in a change of antifungal therapy.17
All-cause mortality rate was similar between the caspofungin group (34.2%)
and the amphotericin B group (30.4%) (p=0.53).17 Similarly, after a post hoc analysis
was performed to determine mortality secondary to candidemia, the rates were similar
between the caspofungin group (4.4%) and the amphotericin B group (7.2%)
(p=0.57).17
Based on the results from this study, superiority cannot be established between
caspofungin and amphotericin B in the treatment of invasive candidiasis; instead, it
can be extrapolated that caspofungin is non-inferior to amphotericin B. However,
what can be established is that caspofungin had a significantly lower number of
adverse events compared to amphotericin B.
Although these results support the caspofungin as an alternative to
amphotericin B in the treatment of invasive Candida infections, there are two factors
that limit its generalizability to our study. First, amphotericin B deoxycholate was
used, which is known to have a more severe adverse effect profile compared to the
liposomal amphotericin B formulation. Secondly, the use of these antifungals was to
treat candidemia and not Candida endocarditis, but what must also be considered is
that data from a prospective cohort (n=187) showed that at least 4.2% of patients with
candidemia have Candida endocarditis.10
20

2.7 Drawbacks to Echinocandins
Although echinocandins may seem like a novel class of antifungals that may
operate as a panacea for invasive fungal infections, it should be noted that like other
therapies designed to treat infections, resistance may develop. This has been shown
through a case report involving a patient in France that demonstrated failure in
treatment with caspofungin for Candida endocarditis.27
C. glabrata was cultured originally and after susceptibility testing, it was
determined that the isolates were susceptible to echinocandins, leading to an initial
treatment with caspofungin.27 After four weeks of treatment with caspofungin, the
patient developed a second infection, which was isolated and identified as C.
tropicalis.27 Treatment was continued with caspofungin, but on hospital day ninetythree, the patient developed a concurrent candidemia with C. albicans.27
Susceptibility testing of the C. tropicalis and C. albicans demonstrated resistance to
all echinocandins caused by a missense mutation that changed the coding of the betaglucan synthase, rendering the echinocandins ineffective.27 Due to this development,
the patient had a treatment change from caspofungin to liposomal amphotericin B
with flucytosine, followed by surgical resection of the vegetation that ultimately led to
a curative outcome to Candida endocarditis and candidemia.27 This report raises
concerns for the use of echinocandins because it was previously thought that only C.
parapsilosis demonstrated slight resistance to echinocandins.4,8,9
2.8 Animal Studies Supporting Echinocandins
A prospective, randomised control trial involving rats (n=18) infected with
Candida endocarditis comprised of C. albicans compared the efficacy between
caspofungin and liposomal amphotericin B.28 The rats were randomised into three
treatment groups based on their intervention—caspofungin, liposomal amphotericin
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B, and placebo.28 Fungal density of the extracted vegetations, the primary outcome,
was measured based on average absorbance of blood cultures from the rats and
showed a significant statistical difference (p<0.05) between the rats that were treated
with an antifungal, either caspofungin or liposomal amphotericin B, and the rats that
received a placebo.28
While the rats that were treated with an antifungal showed no statistically
significant differences, the rats treated with placebo only showed a statistically lower
absorbance, which was similar to the positive control: 0.878 (placebo) versus 0.865
(positive control).28 Conversely, the rats treated with caspofungin had an average
absorbance (0.230), which was similar to the rats treated with liposomal amphotericin
B (0.251).28
The lack of statistically significant difference in the two antifungal treatment
groups lend to the hypothesis that an echinocandin would be non-inferior to liposomal
amphotericin B in the treatment of Candida endocarditis. Furthermore, histological
comparison of the fibrinous vegetations were characterized between the rats treated
with caspofungin and the rats treated with liposomal amphotericin B.28 While both
antifungal treatment groups had reduction in colony size, the caspofungin treatment
group also showed a disruption in the structural integrity of the hyphae, indicating
damage to the membranes of the remaining C. albicans.28 Unlike the caspofungin
treatment group, the liposomal amphotericin B treatment group did not cause any
distortions to the hyphae, which shows that liposomal amphotericin B only affects the
membrane permeability of the Candida species.28
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2.9 Caspofungin, Micafungin, and Anidulafungin
Caspofungin has the highest number of indications of the three echinocandins,
closely followed by micafungin.23 While both caspofungin and micafungin are
approved for treatment of candidemia or invasive candidiasis in both non-neutropenic
and neutropenic adult and paediatric patients, caspofungin has additional indications
through its use in salvage therapy for invasive aspergillosis and empirical treatment of
febrile neutropenia.23
Although caspofungin has been the echinocandin most used in the treatment of
Candida endocarditis publications, it is unknown which of the three echinocandins is
preferred because there is no evidence directly comparing superiority over one
another.3,10,23 The Clinical and Laboratory Standards Institute (CLSI) M27-A3 and the
European Committee on Antimicrobial Susceptibility Testing (EUCAST) were
developed to establish standardized methodologies in the testing of susceptibility of
fungi against available antifungal agents.15 Based on minimum inhibitory
concentrations, pharmacokinetic data, pharmacodynamic data, and animal data,
interpretative breakpoints for susceptibility were established for several antifungal
agents against, in decreasing order of incidence, five of the most common Candida
species—C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei.15
Based on this current data, it is assumed that the three different echinocandins are
equivalent in their fungicidal effects.3,10
Table 5. Clinical Breakpoints for Echinocandins Against Common Candida Species
Candida Species Echinocandin
C. albicans
Anidulafungin
Caspofungin
Micafungin
C. glabrata
Anidulafungin
Caspofungin
Micafungin

Susceptibility
≤0.25
≤0.25
≤0.25
≤0.12
≤0.12
≤0.06
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Intermediate
0.5
0.5
0.5
0.25
0.25
0.12

Resistance
≥1
≥1
≥1
≥0.5
≥0.5
≥0.25

C. parapsilosis

C. tropicalis

C. krusei

Anidulafungin
Caspofungin
Micafungin
Anidulafungin
Caspofungin
Micafungin
Anidulafungin
Caspofungin
Micafungin

≤2
≤2
≤2
≤0.25
≤0.25
≤0.25
≤0.25
≤0.25
≤0.25

4
4
4
0.5
0.5
0.5
0.5
0.5
0.5

≥8
≥8
≥8
≥1
≥1
≥1
≥1
≥1
≥1
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Additionally, there have been no studies that directly observe and analyse the
differences in several pharmacokinetic and pharmacodynamic factors.23 However,
there has been one retrospective study (n=66) showing no statistically significant
differences in mortality rate when treating candidemia or invasive candidiasis with
either micafungin (29.1%) or caspofungin (45.9%).8
While caspofungin has been the echinocandin most often used in case reports,
there is some evidence that micafungin would be a more appropriate alternative.
Micafungin has similar indications in its use of candidemia and Candida endocarditis
in relation to caspofungin, but it has the added benefit of being indicated in
newborns.23 Additionally, unlike caspofungin, micafungin does not require a loading
dose or dosage adjustments for patients with moderate to severe hepatic insufficiency,
making it an attractive alternative for patients with multiple comorbidities.14,15
Additionally, compared to micafungin, caspofungin has been shown to have the most
drug-drug interactions of all echinocandins, specifically affecting the pharmacokinetic
profiles of cyclosporine, tacrolimus, and rifampin.26 Unfortunately, over the last two
decades, caspofungin and micafungin have been used as both first-line treatment and
prophylaxis of candidemia and subsequent infections, leading to the breeding of
echinocandin-resistant Candida species.8,27
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2.10 Micafungin in Candidemia
A prospective, double-blind, randomised control trial (n=531) was conducted
to determine if micafungin (n=264) would be non-inferior to liposomal amphotericin
B (n=267) in the setting of candidemia.14 The primary outcome that was being
investigated between all populations was the response rate of overall treatment
success, which was quantified by both a clinical and mycological response at the
conclusion of antifungal therapy.14
The populations of these groups were further separated into three analysis
populations: per-protocol population (n=202 in the micafungin group, vs. n=190 in
the liposomal amphotericin B group), intention-to-treat population (n=264 in the
micafungin group, vs. n=267 in the liposomal amphotericin B group), and the
modified intention-to-treat population (n=247 in the micafungin group, vs. n=247 in
the liposomal amphotericin B group).14 This specific study had chosen to include
results from both the intention-to-treat and the modified intention-to-treat populations
due to them both being identified as critical information to draw a conclusion of noninferiority.14
When comparing the results from the intention-to-treat population, defined as
those that received at least one dose of the study drug, there was no statistically
significant difference in treatment success when comparing micafungin (71.6%) to
liposomal amphotericin B (68.2%).14 Additionally, after stratification of neutropenic
status, the difference between non-neutropenic patients was 3.9% (CI 95%, -3.911.6).14
The results of the modified intention-to-treat population, which were those
that received at least one dose of the study drug and had confirmed Candida infection,

25

demonstrated no statistically significant difference in treatment success (4.5%)
between micafungin (74.1%) and liposomal amphotericin B (69.6%) (CI 95%, -3.512.4).14 Furthermore, stratification by neutropenic status showed a difference of 4.9%
between non-neutropenic patients, which was still not statistically significant (CI
95%, -3.0-12.8).14
Finally, the results from the per-protocol population, which was the primary
efficacy population, showed similar overall treatment success between the micafungin
group (89.6%) and the liposomal amphotericin B group (89.5%), with a difference in
proportions of 0.1% (95% CI, -5.9-6.2).14 After stratification by neutropenic status,
the difference in proportion between non-neutropenic patients was 0.7% (95% CI, 5.3-6.7).14
Regarding candidemia, similar rates of success were observed between the
micafungin group (90.6%) and the liposomal amphotericin B group (90.8%).14
Mortality rates were similar over the entirety of the study of the intention-to-treat
population of micafungin (40%) and liposomal amphotericin B (40%).14 When
examining if the cause of death was directly related to the fungal infection, it was
noted that, again, the micafungin group (13%) was similar in comparison to the
liposomal amphotericin B group (9%) (p=0.22).14 When specifically looking at
Candida endocarditis, there was a difference in treatment success, but without
statistical significance, between the micafungin group (1/1, 100%) and the liposomal
amphotericin B group (3/4, 75.0%).14 More patients would need to be evaluated in
this setting to allow for an attainment of statistical significance, as well as
generalizability.
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When comparing the treatment-related adverse effects, it was noted that,
overall, there was not a significant difference in adverse effects between micafungin
(43.2%) and liposomal amphotericin B (50.9%) (p=0.082).14 Additionally, micafungin
did not demonstrate any statistically significant differences in serious adverse effects
(4.2%, vs. 7.5% in liposomal amphotericin B; p=0.138) or treatment discontinuation
(4.9%, vs. 9.0% in liposomal amphotericin B; p=0.087).14 However, with micafungin,
there was a statistically significant lower rate of rigors (0.8%, vs. 6.4% with liposomal
amphotericin B group; p=0.0006), increased blood creatinine (1.9%, vs. 6.4% with
liposomal amphotericin B group; p=0.015), back pain (0.4%, vs. 4.5% with liposomal
amphotericin B group; p=0.003), and infusion-related reactions (17.0%, vs. 28.8%
with liposomal amphotericin B group; p=0.001).14
Based on the results of treatment success between the three analysis
populations, it has been shown that micafungin is non-inferior to liposomal
amphotericin B in the primary treatment of candidemia and invasive candidiasis.
Inferences based on these two antifungal therapies cannot be made in reference to
Candida endocarditis due to the limitation of having only five patients within the
study.14 However, although non-inferior to liposomal amphotericin B, micafungin
showed superiority in safety profile compared to liposomal amphotericin B,
specifically in renal function and infusion-related events. This data related to safety
profile bridges the gap in literature from the study comparing caspofungin and
amphotericin B deoxycholate because there is now evidence comparing
echinocandins and liposomal amphotericin B.
2.11 Case Reports Using Liposomal Amphotericin B in Candida Endocarditis
While conducting our literature review, we summarized recent case reports
that used a liposomal amphotericin B-based treatment regimen in the setting of
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Candida endocarditis. All included cases had a diagnosis of Candida endocarditis
through multiple, positive blood cultures and vegetations visualized either by
transthoracic and/or transoesophageal echocardiography. All cases reported successful
treatment of Candida endocarditis with or without use of adjunctive surgery, which
should be noted as a potential bias that the researchers have identified. Table 5
contains a brief summary of information regarding each case report.
Table 6. Case Reports Using Liposomal Amphotericin B
Reference
Bauer7

Age/
Sex
64/M

Gardiner29

56/M

Checchia3

56/M

C. krusei

49/M

C. tropicalis L-AMB for 8 weeks

0

Pipa31

Candida
Therapy
Species
C. tropicalis L-AMB 5 mg/kg/d +
5-FU 25 mg/kg QID
for 26 days
Dose reduction of LAMB to 3 mg/kg for
rising Cr for 30 days
C.
Ani 200 mg for 4
parapsilosis days
L-AMB 5 mg/kg/d +
5-FU 500 mg QID for
17 days
Discontinuation of LAMB due to renal
toxicity
Ani 200 mg + fluc
800 mg for 6 weeks

AmB 50 mg/d for 4
weeks
Ani 100 mg for 24h
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Surgery
-

Outcome

14month
follow
up
without
relapse
Day 149
found
dead
from
heroin
overdose
Postmortem
examinat
ion: no
evidence
of fungal
endocard
itis
Heart
6-week
transplantat follow
ion after
up
amp-deox
without
relapse
MV and
8-week
AV
follow
mechanical up
prosthesis
without
during Lrelapse
ampB
therapy

5-FU – Flucytosine; AmB – Amphotericin Deoxycholate; Ani – Anidulafungin; AV
– Aortic Valve; Cr – Creatinine; Fluc – Fluconazole; L-AMB – Liposomal
Amphotericin B; MV – Mitral Valve; QID – quater in die
2.12 Liposomal Amphotericin B with Flucytosine in Candida Endocarditis
In a recent retrospective study (n=46) of Candida endocarditis, thirty-one
patients (67%) received antifungal therapy alone.32 Of the thirty-one patients,
seventeen (55%) received liposomal amphotericin B with flucytosine and fourteen
(45%) received an echinocandin, either caspofungin or anidulafungin.32 From the
subset of patients that were receiving liposomal amphotericin B with flucytosine, ten
developed renal insufficiency, leading to its discontinuation in three patients.32
Although more patients developed renal injury in this treatment group, it was noted
through univariate analysis that compared to all other induction antifungal therapies,
liposomal amphotericin B with or without flucytosine (26% survival without
flucytosine; 33% survival with flucytosine) was associated with a lower six-month
mortality rate.32 During review of six-month survival rate by multivariate analysis, it
was noted that patients receiving liposomal amphotericin B-based monotherapy had a
higher survival rate than those receiving an echinocandin-based monotherapy (95%
CI, 1.03-838.10; aOR 13.52).32 Through the evidence provided by this study, the data
supports the recommendation of having the primary pharmacological therapy for
Candida endocarditis consisting of a liposomal amphotericin B-based therapy, more
specifically, one that includes the use of flucytosine.
A meta-analysis totalling 879 cases of reported Candida endocarditis between
1966-2002 reviewed 418 reports.2 Through the authors’ inclusion criteria of definitive
Candida endocarditis, 105 reports containing a total of 163 patients were reviewed.2
In order to reflect current medical practices, cases after 1980 (n=92), which was the
decade where echocardiography technology emerged, were summarized with greater
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detail by including location of cardiac valve involvement, type of infected valve, and
specific treatment details.2
These cases were divided based on pharmacological and/or surgical
treatment—medical antifungal monotherapy (n=15), medical antifungal combination
therapy (n=19), and medical antifungal therapy with adjunctive surgery (n=58).2
Within the medical antifungal monotherapy group, 53.3% (8/15) had reported
successful outcomes.2 The most commonly used antifungal was amphotericin B
(53.3%), which had the second highest reported successful outcome (75.0%).2 The
second most commonly used antifungal was fluconazole (40.0%), which resulted in a
successful outcome of 16.7%.2 Flucytosine monotherapy had the highest reported
treatment success (100%); however, it should be noted that only one patient was
treated with flucytosine monotherapy.2
Within the medical antifungal combination therapy group, 63.2% (12/19) had
successful reported outcomes.2 The most commonly used medical antifungal
combination therapy was amphotericin B with flucytosine (73.7%), which had the
third highest reported successful outcome (63.2%), following amphotericin B with
fluconazole (66.7%) and amphotericin B with rifampin and flucytosine (100%).2
However, similar to the monotherapy group, it should be noted that the number of
patients treated with amphotericin B with fluconazole and amphotericin B with
rifampin and flucytosine were comprised of three and one patients, respectively.2
With the use of meta-regression analysis techniques and using mortality as the
outcome, mortality was highly associated in patients that were treated with antifungal
monotherapy (95% CI, 0.39-5.81; Prevalence Odds Ratio (POR) 1.49).2 The findings
from this meta-analysis suggest that when treating Candida endocarditis with medical
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therapy alone, combination therapy is preferred to monotherapy alone.2,4 Additionally,
although the medical antifungal combination therapy of amphotericin B with
flucytosine had the third highest rate of successful reported outcomes, the two
medical antifungal combination therapies with higher reported successful outcomes
were not sufficiently powered, making them lack statistical significance.
While this meta-analysis shows a higher rate of treatment success with
amphotericin B-based combination therapy, it must be noted that this study did not
include the use of any echinocandin-based therapy.
2.13 Case Reports Using Echinocandins in Candida Endocarditis
During our review of recent literature, we summarize case reports that use
echinocandins in the setting of Candida endocarditis. The case of the 69-year-old
male was given a clinical diagnosis of Candida endocarditis via two major criteria
(persistently positive blood cultures and evidence of endocardial involvement)
because the transoesophageal echocardiogram only revealed fibrin stranding.13 This
patient’s clinical diagnosis was further supported by the presence of three minor
criteria (fever above 38.0°C, predisposing lesion, and echocardiographic findings
consistent with infective endocarditis, but do not meet major criteria).13
All other cases had a diagnosis of Candida endocarditis through multiple,
positive blood cultures and transthoracic and/or transoesophageal echocardiography.
The majority of case reports resulted in treatment success of Candida endocarditis
with and without the use of adjunctive surgery, which should be noted as a potential
bias that the researchers have identified. More details are provided on these cases in
Table 7.
Table 7. Case Reports Using Echinocandins
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Reference
Morioka9

Age/
Sex
80/M

Ahuja13

69/M

Ahuja13

45/M

Kubota33

31/F

Surgery

Outcome

L-AMB 3 mg/kg/d for
8 days
Discontinuation of LAMB due to rising Cr
Mica 150 mg/d + fluc
200 mg/d for 6 weeks
C.
L-AMB 5 mg/kg/d
parapsilosis Discontinuation of LAMB due to rising
creatinine
Mica 150 mg + fluc
400 mg for 12 weeks
C.
Mica 150 mg + fluc 6
parapsilosis mg/kg for 2 weeks
L-AMB 5 mg/kg/d + 5FU 2500 mg Q6H +
fluc 400 mg/d for 1
week
Discontinuation of LAMB due to rising Cr
Mica 150 mg/d + fluc
400 mg/d + 5-FU 2500
mg/d followed by an
increase in 5-FU to
2500 mg Q8H for 12
weeks
C. albicans L-AMB 200 mg/d for 4
days
Discontinuation of LAMB due to rising Cr
L-AMB 200 mg/d for
14 days
Discontinuation of LAMB due to rising Cr
Mica 150 mg/d + fluc
400 mg/d for 54 days
C. tropicalis Caspo 70mg for 1 day
Caspo 50mg for 10
days
Fluc for 15 days

AV
bioprosthe
sis during
mica and
fluz

6-month
follow
up
without
relapse

-

1-year
follow
up
without
relapse

-

5-month
follow
up
without
relapse

Removal
of
prosthetic
valves
during
mica
therapy

6-week
follow
up
without
relapse

-

19/M

C. albicans

Caspo + fluc for 8
weeks

PM
replaceme
nt

70/F

C. glabrata

Caspo 70mg for 2 days

2-month
follow
up
without
relapse
3-month
follow
up
without
relapse
Decease
d day 31

Bandyopa 86/M
dhyay34

DuranteMangoni3

Candida
Species
C.
parapsilosis

Therapy

5

GlavisBloom36

32

-

Glockner3 69/F

Follow
up (no
timefram
e)
without
relapse
Jagernaut 54/M C. albicans Caspo for 3 months
PV/TV
No
h38
replaceme follownt
up
5-FU – Flucytosine; Ani – Anidulafungin; Caspo – Caspofungin; Cr – Creatinine;
Fluc – Fluconazole; L-AMB – Liposomal Amphotericin B; Mica – Micafungin; PM
– Pacemaker; PV – Pulmonary Valve; TV – Tricuspid Valve
7

C. albicans

Caspo 100mg + 5-FU
37.5mg BID
Discontinuation of
caspo due to
hepatotoxicity
Mica + 5-FU for 3
weeks
Ani 200mg for 1 day
Ani 100mg for 30 days

-

2.14 Review of Studies to Identify Possible Confounding Variables
Throughout the extensive literature review, it has been noted that there are
several confounding variables that have influenced the generalizability of conducting
this study. Most of these confounding variables will be attempted to be curbed
through the use of a highly specific exclusion and inclusion criteria, as well as
stratification of subgroups during statistical analysis.
Although C. albicans has historically been identified as the species of Candida
to most often cause Candida endocarditis and candidemia, the prominent global use of
azoles for prophylaxis and treatment has been associated with the epidemiological
shift to other Candida species.8,16 Local epidemiology describing the species of
Candida need to be considered for empiric treatment of invasive Candida
infections.8,16 This will be done by stratification based on recruitment site.
Mortality is directly correlated with delays in both the identification of
Candida endocarditis and choice of the most efficacious antifungal agent.6,16
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Identifying the infectious source is extremely important in the management of
Candida endocarditis and candidemia—whenever possible, infected medical devices
need to be promptly removed and abscesses need to be drained.10,14,16 Failure to
quickly identify and address these infectious sources is correlated with increased
mortality while swift intervention to achieve source control to reduce fungal inoculum
is correlated with improved clinical outcomes.6,10,16
Only patients diagnosed with proven and probable Candida endocarditis will
be included in the study to avoid bias related to the pathogenic characteristics specific
to other fungal pathogens.5 After identification of patients with proven Candida
endocarditis, comorbid conditions that have been acknowledged as independent
predictors of all-cause mortality will need to be taken into account. Acute heart failure
has been recognised as an independent predictor of all-cause mortality, as well as
glycaemic control in diabetic patients needing to be optimized.5,16 Finally, if clinically
possible, the use of immunosuppressive and/or antibacterial therapies should be
decreased or stopped.16
2.15 Review of Relevant Methodology
To our knowledge, all published clinical trials investigating the efficacy and
safety of an amphotericin B-based regimen or an echinocandin-based therapy have
been through the use of randomised control trials or retrospective
analyses.2,5,8,14,17,18,22,28,32 Based on our goal of determining non-inferiority, our study
was designed as a randomised control trial to allow for control of patients and
treatment options.
Patients 16 years of age or older were eligible for recruitment into the study.14
Non-neutropenic patients receiving an azole-based systemic antifungal prophylaxis
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for three or more days within the last seven days were ineligible for recruitment into
the study.14 Neutropenic patients, defined as having an absolute neutrophil count less
than 500 cells per microlitre, receiving antifungal prophylaxis were eligible for
recruitment into the study.14
The modified Duke Criteria was developed in aiding the diagnosis of infective
endocarditis; however, it was created through data from bacterial endocarditis.4 There
are currently no diagnostic criteria that are specific to the identification of fungal
endocarditis.4 Utilization testing for the Mannan antigen and the anti-mannan
antibodies is another useful diagnostic tool due to the combined sensitivity of 83%
and specificity of 86% for Candida endocarditis.4,6 The downfall to this diagnostic test
is that empiric treatment with antifungals can lower the levels of the Mannan antigen
and anti-mannan antibodies.4 Based on this information, the modified Duke criteria,
positive candidemia cultures, and utilization of the transthoracic and/or
transoesophageal echocardiogram will be used to determine Candida endocarditis
diagnosis.
While on either the echinocandin-based or liposomal amphotericin B-based
therapy, clinical success has been documented in patients that received treatments for
six to eight weeks.6 In the setting of Candida endocarditis, it would be considered
inappropriate to treat with either medical therapy for less than four weeks.6
In order to determine cessation of candidemia, daily blood cultures must be
drawn until sterilisation of the blood is noted.6,10 Upon clearance of candidemia, the
general consensus is to continue antifungal treatment for an additional two weeks, but
there is no experimental data supporting this clinical decision.10
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2.16 Conclusion
The existing evidence provided by a series of case studies, meta-analyses, and
randomised control trials have demonstrated promise in the use of micafungin as a
non-inferior alternative to liposomal amphotericin B with flucytosine for the treatment
of Candida endocarditis. With micafungin providing several instances of successful
treatment of Candida endocarditis, as well as a more tolerated side effect profile, this
choice of echinocandin is the next logical choice for further investigation in the
treatment of this deadly disease. Comparison of all-cause mortality from initiation of
the assigned study medication to the end of treatment as the primary outcome,
together with measuring time to clearance of candidemia, assessing safety profile
through adverse side effects, and identifying relapse of Candida endocarditis after
initiation of step-down therapy as secondary outcomes will provide the setting for this
study to produce meaningful results.
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Chapter 3 – Study Methods
3.1 Study Design
We will be performing a prospective, randomized, double-blind, international,
multicentre, non-inferiority clinical trial comparing liposomal amphotericin B and
flucytosine versus micafungin for the primary treatment of Candida endocarditis.
Enrollment will be conducted between January 2021 to June 2022 based on
convenience sampling. Study participants will be randomized to the control group
(liposomal amphotericin B with flucytosine) or intervention group (micafungin) using
a third-party, computerized random number generator. Data collection will be
conducted between July 2022 to December 2022.
3.2 Study Population and Sampling
Patients 16 years or older will be eligible if they are considered to meet the
criteria of infective endocarditis set by the modified Duke criteria,1 as well as criteria
for probable or proven candidemia.2 Key inclusion and exclusion criteria will be
further discussed in the following sections, with full criteria being found in the
appendix. Only patients that meet all inclusion criteria and none of the exclusion
criteria will be eligible to participate in the study, which will include a preliminary
screening visit that will include, but not be limited to, physical examinations and
blood samples. Due to the rarity of Candida endocarditis, convenience sampling will
be utilized with a 1:1 allocation to assign subjects to receive either amphotericin B
with flucytosine or micafungin.
3.3 Inclusion Criteria
The following inclusion criteria will be disseminated to participating sites to
screen potential study participants: patients 16 years or older that meet that pathologic
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criteria and clinical criteria of definite infective endocarditis.1 After initial screening,
participants will be categorized into criteria for proven, probable, and possible
Candida endocarditis.2 Once complete, only the participants that have met the criteria
for proven or probable Candida endocarditis will be included into the study. In
addition to meeting these key inclusion criteria, patients will also be screened via
blood sampling to determine renal function based on creatinine levels. A full list of
inclusion criteria can be found in the appendix.
3.4 Exclusion Criteria
Key exclusion criteria will be distributed to participating sites. If either of the
key exclusion criteria are met, the patient will be deemed ineligible for recruitment
due to the contraindications of liposomal amphotericin B with flucytosine
administration. These key exclusion criteria included patients with moderate-to-severe
renal insufficiency, defined as a calculated creatinine clearance <50 mL/min.3
Additional exclusion criteria includes known hypersensitivity or allergy history to the
proposed study medications and/or their adjuvant components,3 acute heart failure,4
patients with poor glycaemic control,5 and body weight less than forty kilograms.6
Antifungal prophylaxis will be considered a relative exclusion criterion—nonneutropenic patients on systemic antifungal prophylaxis for three or more days within
the last seven days will be excluded, but neutropenic patients on antifungal
prophylaxis will be allowed to be included.6 A full list of exclusion criteria can be
found in the appendix.
3.5 Subject Protection and Confidentiality
This study will be reviewed by the Institutional Review Board (IRB) or
independent ethics committees at each of the participating sites. All eligible patients
will be given information verbally by study personnel. If interested, these patients will
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then be given a study brochure that will detail all pertinent information to be enrolled
in the study. Once the patient decides to partake in the study, he or she will be
required to give verbal consent, as well as written consent by signing an IRBapproved consent form. This consent form will outline the purpose of the study, the
two treatment groups, randomization procedures, requirements of the patient, timeline
of the study, and possible treatment-related adverse effects. If the patient wishes to
withdraw from the study at any point in time, the IRB-approved consent form will
detail how to formally withdraw from the study. The study brochure and IRBapproved consent form will be included in the appendix.
In order to maintain confidentiality of patients, the research conducted in this
study will adhere to policies and regulations set forth by the Health Insurance
Probability and Accountability Act (HIPAA). All identifying patient information will
be kept strictly confidential with IRB-approved patient database. Additionally, all
study personnel will be required to undergo HIPAA training and certification.
Documentation of this training and certification will be kept by the principal
investigators.
3.6 Recruitment
In order to participate in the study, interested healthcare facilities will be
required to have their governing bodies approve of the study protocols and any
amendments that may be made. Once recruited, the participating study sites will
facilitate the enrolment of patients to obtain the required sample size by providing the
eligible, interested patients with further study information, including the study
brochure. In the event that the patient is unable to make medical decisions for himself
or herself, consent for enrolment into the study must be obtained by the legally
authorized representative of the patient.
42

3.7 Study Variables and Measures
The intervention of this study will be the administration of micafungin at
150mg IV daily with a placebo PO QID to maintain blinding. The control for this
study will be the standard of care, which is liposomal amphotericin B 4mg/kg IV
daily with flucytosine 25 mg/kg PO QID.7 Both interventions will be given for a
minimum of six weeks, but no longer than eight weeks.7
The primary dependent variable will be an all-cause mortality from the day of
assigned study drug regimen to day fifty-six. Day fifty-six was chosen due to the
maximum therapy duration for Candida endocarditis being eight weeks.7
Secondary dependent variables will include time to clearance of candidemia,
assessment of adverse effects, and determination for the incidence of relapse of
Candida endocarditis after the initiation of step-down maintenance therapy. After
identification of the Candida species, susceptibility testing will be conducted and the
appropriate step-down therapy (PO voriconazole 200-300 mg (3-4 mg/kg) BID, longacting posaconazole 300 mg daily, or fluconazole 400-800 mg (6-12 mg/kg) daily)
will be administered.7
3.8 Blinding of Intervention
All personnel involved in the study were blinded to treatment allocation,
except for two research pharmacists at each participating study site. One research
pharmacist would be responsible for the preparation and dosing of medications, which
would be blinded during administration via opaque coverings on medication
administration sets. If placed in the intervention group (micafungin), the patient
would also be given a placebo at the frequency of flucytosine administration in the
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control group. The second research pharmacist would be responsible for reviewing
drug accountability records.
3.9 Blinding of Outcome
The study participants will be blinded to the primary and secondary outcomes
while being treated in the inpatient setting. The researchers will be blinded to the
primary or secondary outcomes while treating the patients in the inpatient setting.
3.10 Assignment of Intervention
Patients will be randomly assigned to either receive 150mg of micafungin IV
daily with a placebo PO QID or 4mg/kg of liposomal amphotericin B IV daily with
25mg/kg of flucytosine PO QID for 8 weeks. Randomisation will be conducted in a
1:1 ratio and stratification will be conducted based on treatment site, as well as
baseline neutropenic status. In addition, a third-party computer program will be used
to generate randomisation to ensure true random probability for treatment allocation
at each site. This use of the third-party computer program will maintain the integrity
of our results.
3.11 Adherence
Adherence to the allocated treatment would be maintained through research
personnel. Study participants would not be expected to administer the medication
themselves; therefore, interventions will only be administered within the inpatient
setting of the study participants’ hospitalisation. Supervision of adherence will be
maintained through the use of study nurses at the study sites through their
documentation of study medication administration. Additionally, prior to the first
administration of the assigned treatment regimen, all indwelling catheters will be
removed.
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3.12 Monitoring of Adverse Events
Study participants will be informed to notify investigators of any adverse
effects they are experiencing. Investigators will record the reported adverse effects on
a standardised form and will categorise these adverse effects based on PRO-CTCAE.
In addition to recording these reported adverse effects, study participants will also
have daily morning assessment of their serum chemistry laboratories, such as
complete blood count, complete metabolic panel, electrolyte panels, etc. and
categorised based on the PRO-CTCAE.
3.13 Data Collection
All necessary data of the study participants will be recorded via the patient’s
online medical records, as well as a separate form in order to maintain accumulation
of mandatory information for statistical analysis of the primary and secondary
outcomes.
Assessment of probable and proven Candida endocarditis will be done at
baseline, weekly during the treatment phase, and at the end of therapy using the
modified Duke Criteria. Assessment of probable and proven candidemia will be done
at baseline, weekly during the treatment phase, and at the end of therapy using the
EORTC/MSG.
The primary endpoint is all-cause mortality at day fifty-six and based on
whether the study participant had expired from any cause in the hospital. The
secondary endpoint of measuring time to clearance of candidemia will be determined
through two sets of negative blood cultures. Additionally, drug-related adverse effects
will be documented based on categorisation of PRO-CTCAE throughout the entirety
of the treatment phase. Finally, identification of relapse will be assessed for patients
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that experience treatment success through the treatment phase but showed reemergence of the same Candida isolates after completion of IV treatment.
3.14 Sample Size Calculation
We based our sample size calculation on all-cause mortality published by an
observational cohort study that examined Candida endocarditis with a specific focus
on therapy modalities.8 However, due to the scarcity of data in regard to micafungin
success specifically in Candida endocarditis, the rate of success in Candida
endocarditis is from echinocandins as a class instead of individually.8 In order to
calculate sample size, a program called Sealed Envelope Limited 2012 – Power
Calculator for Binary Outcome Non-Inferiority Trials was used.
Assuming liposomal amphotericin B with flucytosine has a successful
response rate of 55% (45% mortality rate) and micafungin has a successful response
rate of 64% (36% mortality rate), (α=0.05, β=0.2, δ=0.10) it was determined that a
total of 82 patients per treatment group were needed to determine non-inferiority.6,9-11
This would result in a need for roughly 164 patients in the study; however, we are
planning to enrol a total of 223 patients through the assumption of the need to exclude
36% of patients from the per-protocol set.6
3.15 Statistical Analysis
Although this study will be conducting statistical analyses of the primary and
secondary endpoints of the per-protocol population, the intention-to-treat (ITT)
population and the modified intention-to-treat population (mITT) will be of most
interest and significance. The ITT population, the primary efficacy population, will
include all patients that were enrolled, randomised, and received at least one dose of
either experimental treatment therapy.3 The primary efficacy endpoint will be all-
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cause mortality from the first dose of the assigned therapy to day fifty-six in the ITT
population because this population would best represent the patients receiving
antifungal treatment in a real-wold setting.3,6 Additionally, the mITT population will
be essential in drawing the conclusion of non-inferiority because this population will
consist of the number of study participants that were determined to have probable or
proven candidemia, based on the EORTC/MSG.6
Continuous variables will be presented as the median and interquartile range
and will be compared using the Mann-Whitney test. Categorical variables will be
presented as numbers and percentages that will compared using either the Chi-square
test or Fisher’s exact test.
3.16 Timeline and Resources
Our proposed study will take approximately two years, which will include
subject recruitment, baseline assessment, and follow-up period. We anticipate
beginning our study in January 2021 with subject recruitment, which will extend to
June 2022, totalling eighteen months (months 0-18). The proposed timespan for
recruitment will allow for our study to maximize recruitment and develop a study
population that will hopefully be generalisable to the interested population. This will
allow for six months of completing the assigned regimen, which will be administered
for no less than four weeks, but no more than eight weeks (months 18-20).7 If
clearance of candidemia is achieved, the assigned antifungal therapy will continue for
an additional two weeks per standard of care (month 20).12 In order to abide by
recommendations for the treatment of Candida endocarditis, patients will be given an
appropriate step-down therapy.7 Follow-up after step-down therapy will determine
resurgence of candidemia and/or Candida endocarditis within a twelve-week period
(months 21-24).6
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This period of twenty-four months will not include time to IRB approval or
the proposed data analysis. It is anticipated that approval for this study by the IRB
will take approximately four months. Additionally, we predict that data analysis will
take no more than five months.
The required resources for this study will largely be covered by the recruited
study sites. The only foreseeable additional charge that will affect these institutions is
recruitment of research assistants. The need for additional research assistants will be
decided by each site.

48

References
1.

2.

3.

4.

5.
6.

7.

8.

9.
10.

11.
12.

Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria
for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633638.
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive
fungal disease from the European Organization for Research and Treatment of
Cancer/Invasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821.
Maertens JA, Raad, II, Marr KA, et al. Isavuconazole versus voriconazole for
primary treatment of invasive mould disease caused by Aspergillus and other
filamentous fungi (SECURE): a phase 3, randomised-controlled, noninferiority trial. Lancet. 2016;387(10020):760-769.
Siciliano RF, Gualandro DM, Sejas ONE, et al. Outcomes in patients with
fungal endocarditis: A multicenter observational cohort study. Int J Infect Dis.
2018;77:48-52.
Whitney LC, Bicanic T. Treatment principles for Candida and Cryptococcus.
Cold Spring Harb Perspect Med. 2014;5(6).
Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal
amphotericin B for candidaemia and invasive candidosis: a phase III
randomised double-blind trial. Lancet. 2007;369(9572):1519-1527.
Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for
the Management of Candidiasis: 2016 Update by the Infectious Diseases
Society of America. Clin Infect Dis. 2016;62(4):e1-50.
Arnold CJ, Johnson M, Bayer AS, et al. Candida infective endocarditis: an
observational cohort study with a focus on therapy. Antimicrob Agents
Chemother. 2015;59(4):2365-2373.
Fay MP, Follmann DA. Non-inferiority tests for anti-infective drugs using
control group quantiles. Clin Trials. 2016;13(6):632-640.
Spellberg B, Talbot G. Recommended design features of future clinical trials
of antibacterial agents for hospital-acquired bacterial pneumonia and
ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51 Suppl
1:S150-170.
Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for
invasive candidiasis. N Engl J Med. 2007;356(24):2472-2482.
Mellinghoff SC, Cornely OA, Jung N. Essentials in Candida bloodstream
infection. Infection. 2018;46(6):897-899.

49

Chapter 4 – Conclusion
Candida endocarditis is a rare and deadly disease.1 It has been shown to be an
issue for both non-neutropenic and neutropenic patients.2-4 Research regarding this
infection is scarce, with the only data supporting the current standard of care being
from five decades of successful treatment in case reports.4,5 Furthermore, the evidence
to show a possible alternative to the standard of care is from successful treatments in
case reports as well. Gaps in knowledge around Candida endocarditis will continue if
there are no prospective randomized control trials conducted. This proposed study
aims to determine if the recommendations for the treatment of Candida endocarditis
can be given evidence in a controlled study. If effective, recommendations by the
IDSA and ESCMID will finally be able to support their strong recommendations with
high-quality evidence instead of low-quality evidence.4,6,7
4.1 Study Advantages
If this study is approved, there are a plethora of benefits that will be provided
by the gathered data. To date, this will be the first prospective randomised control trial
to compare the standard of care for Candida endocarditis to a novel antifungal
therapy. By providing evidence of non-inferiority, the primary outcome, and taking
advantage of existing data of echinocandins, specifically micafungin, an alternative
treatment can be provided to patients. Additionally, the existing literature today has
primarily observed the use of caspofungin on Candida endocarditis. This study will
broaden our knowledge on one of the lesser used echinocandins, in this specific
context, micafungin.
Based on the results of the secondary outcomes, several benefits could be
drawn from that data. Through analysis of the adverse effects, combined with the
existing data from the literature review, we will be able to determine if micafungin is
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not only an alternative to Candida endocarditis based on efficacy, but also if
micafungin is safer and/or more tolerable for patients. Through the isolation of
Candida species, we will also be able to characterise epidemiological differences
between Candida species in different areas of the world. This will provide more
information for practitioners so that empirical treatment can be more evidence-based.
4.2 Study Disadvantages
Unfortunately, like all other studies, our study will have its disadvantages.
Despite having a prolonged period for recruitment, it is assumed that the majority of
the patients will be non-neutropenic because Candida infections are showing growing
incidence through the increased use of illicit intravenous drugs.2-4 Similar to most
mycological studies, we attempt to reduce this generalizability bias through
stratification of study participants into groups of neutropenic patients and nonneutropenic patients. Additionally, we cannot generalize our results to patients with
renal insufficiency, acute heart failure, underweight patients, or patients with poor
glycaemic control because they were excluded through each of these factors being
confounding and independent to mortality.
Furthermore, this study will not give any information or data regarding
adjunctive surgery, such as optimal timing and necessity of the surgery. This study
will only be examining pharmacological therapy. Finally, our study will be
monitoring the efficacy of micafungin monotherapy. There have been studies, not
involving echinocandins however, demonstrating superiority of combination
antifungal therapy, but there is not enough information nor published case reports to
suggest which antifungals may be best to pair with micafungin or other
echinocandins.
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4.3 Clinical and/or Public Health Significance
As incidence of Candida endocarditis increases, there is a definitive need for
evidence-based medicine to guide optimal management of this deadly infection.
Historically, amphotericin B deoxycholate has been used, but was limited in its use
through significant renal toxicity.8 Although there has been a development of a lesser
nephrotoxic formulation, liposomal amphotericin B, it still has a high propensity to
cause damage to the kidneys and is extremely expensive.8 The data from this study
would have the potential of being a landmark study through evidence of a less
expensive, more tolerable, and possibly non-inferior alternative in treating this deadly
disease—echinocandins.
4.4 Future Studies
Depending on the results from our proposed trial, there are a series of logical
steps that can be taken in the treatment of this mycological heart infection. If noninferiority is shown with micafungin, future studies can observe the efficacy of the
other lesser used echinocandin, anidulafungin. Furthermore, since it was determined
that combination therapy is superior to monotherapy in the pharmacological treatment
of Candida endocarditis, future studies could investigate what antifungal drugs could
be best combined with echinocandins.
Additionally, based on the literature review performed, future studies could
evaluate adjunctive surgery for Candida endocarditis. One future study that should be
addressed would be the most appropriate time for adjunctive surgery after the
initiation of pharmacological therapy. There is no recommendation regarding when
adjunctive surgery should take place after initiation of antifungal therapy. Conversely,
a future study should be performed to determine if adjunctive surgery is as mandatory
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as it has been cited to be. Several case reports have already shown that optimal
medical therapy could obviate the need for adjunctive surgery.

53

References
1.
2.

3.
4.

5.

6.

7.

8.

Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus
surgical therapy for Candida endocarditis. J Infect. 2005;51(3):230-247.
Kauffman CA. Complications of Candidemia in ICU Patients:
Endophthalmitis, Osteomyelitis, Endocarditis. Semin Respir Crit Care Med.
2015;36(5):641-649.
Ammannaya GKK, Sripad N. Fungal endocarditis: what do we know in 2019?
Kardiol Pol. 2019.
Pasha AK, Lee JZ, Low SW, Desai H, Lee KS, Al Mohajer M. Fungal
Endocarditis: Update on Diagnosis and Management. Am J Med.
2016;129(10):1037-1043.
Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and
amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):20202029.
Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for
the Management of Candidiasis: 2016 Update by the Infectious Diseases
Society of America. Clin Infect Dis. 2016;62(4):e1-50.
Arnold CJ, Johnson M, Bayer AS, et al. Candida infective endocarditis: an
observational cohort study with a focus on therapy. Antimicrob Agents
Chemother. 2015;59(4):2365-2373.
Scudeller L, Viscoli C, Menichetti F, et al. An Italian consensus for invasive
candidiasis management (ITALIC). Infection. 2014;42(2):263-279.

54

Appendices
Appendix A. Candida Endocarditis Data Collection
Subject Participant Number:
Age:
Sex:
Race:
Neutropenic Status:
Assigned Group:
Candida Endocarditis Status: Please list prespecified criteria for diagnosis
Species:
Initiation Date of Assigned Medication:
Date of Candidemia Clearance: if applicable
Date of Candida Endocarditis Clearance: if applicable
Adverse Effect & Grade: Please refer to attached documentation for grading
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Appendix B. Sample HIC Consent Form
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
200 FR.1
YALE UNIVERSITY SCHOOL OF MEDICINE
Study Title: Liposomal Amphotericin B and Flucytosine Versus Micafungin in
Treatment of Candida Endocarditis
Principal Investigator: Dr. Matthew Grant, MD
Co-Investigator: Anton Matthew Yanker, PA-SII
Funding Source: Yale School of Medicine
Invitation to Participate and Description of Project
We are inviting you to participate in a research study designed to look at the
efficacy of two different antifungal treatments in the setting of Candida Endocarditis.
You have been asked to participate because you are highly suspected of being
affected of Candida endocarditis. Approximately 200 individuals will be participating
in the study.
In order to decide whether or not you wish to be a part of this research study,
you should know enough about its risks and benefits to make an informed decision.
This consent form gives you detailed information about the research study, which a
member of the research team will also discuss with you. This discussion should take
place over all aspects of this research study—its purpose, procedures that will be
performed, any potential risks of the procedures, possible benefits, and possible
alternative treatments. Once you understand the study, you will be asked if you wish
to participate. If you agree, you will be asked to sign this form.

Description of Procedures
If you agree to participate in this study, you will be randomly assigned to receive
either (a) liposomal amphotericin B with flucytosine, OR (b) micafungin with
placebo.
In this study program, you will be asked to adhere to your assigned medication
regimen at the prespecified frequency and dosage. The study nurses will be providing
the medications to you at scheduled times, dosages, and frequencies. You will remain
in the hospital for the duration of the treatment, which will last no longer than fifty-six
days. Blood draws will be obtained daily to monitor candidemia levels and to gather
information about standard laboratory information, such as complete blood counts and
metabolic panels. Transthoracic and/or transoesophageal echocardiograms will be
conducted as well to determine the presence of Candida endocarditis.
Throughout the entirety of the study, the investigators will ask you to document
and/or report any adverse effects you are feeling that you believe may be a result of
your study medication regimen.
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A description of this study will be available on http://www.ClinicalTrials.gov, as
required by U.S. Law. (See Clinical Trials Identifier Number xxxxxxxxxx). This
website will not include information that can identify you. The purpose of this
database is to allow everyone to see information on what studies are being done, and
what studies have already been done. At most, the website will include a summary of
the results. You can search this website at any time.
You will be told of any significant new findings that are developed during the course
of your participation in this study that may affect your willingness to continue to
participate. Research results will not be returned to your clinician. If research results
are published, your name and other personal information will not be disclosed or
given.

Risks and Inconveniences
Liposomal amphotericin B has been used for several years and studied in a number of
clinical trials for many fungal infections. The most common adverse effect is
nephrotoxicity and infusion-related events. Flucytosine has also been used for several
years and studied in a number of clinical trials. The most common adverse effect is
myelotoxicity after prolonged usage. Therapeutic-drug monitoring will be conducted
to watch for serious adverse effects; however, we would like you to report any
adverse effects you may be experiencing.
Micafungin is another antifungal drug that has been used for several years and studied
in a number of clinical trials. To our knowledge, the resulting adverse effects are
minimal in severity.
Other risks from participating in the study include the breach of confidentiality about
your health status and participation in the study. This is unlikely to happen, as all
study investigators are trained and certified in research privacy, as well as HIPAA.
We will also ask you to have your blood drawn daily. The risks involved in
venepuncture include, but are not limited to, momentary discomfort at the site of the
blood draw, possible bruising, redness, and swelling around the site, bleeding at the
site, feeling of lightheadedness when the blood is draw, and rarely, infection at the
site of venepuncture.

Benefits
The potential benefit resulting from the study includes full treatment of candidemia
and/or Candida endocarditis. This study may also provide better insights to treatment
guidelines for this rare and deadly disease, which may lead to more treatment success
in the future.
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Economic Considerations
The medications will be provided to you free of charge. There are no other costs
associated with your participation in the study. Parking will also be provided free of
charge to visitors.

Treatment Alternatives/Alternatives
If you choose not to participate in this study, there are no alternative treatments
available, except those that are already being administered by your treatment team,
including pharmacotherapy (medications/drugs). You may choose not to participate.

Confidentiality and Privacy
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
State law. Examples of information that we are legally required to disclose include
abuse of a child, abuse of an elderly person, or certain reportable diseases.
Information will be kept confidential by using only identification numbers on study
forms, storing signs forms in locked cabinets, and password protecting data to be
stored on a computer. When the results of the research are published or discussed in
conferences, no information will be included that would reveal your identity unless
your specific permission for this activity is obtained.
We understand that information about your health is personal and we are committed
to protecting the privacy of that information. If you decide to be in this study, the
researcher will get information that identifies your personal health information. This
may include information that might directly identify you, such as name, address,
telephone number, email address, and/or mobile phone number. This information will
be de-identified at the earliest reasonable time after we receive it, meaning we will
replace your identifying information with a code that does not directly identify you.
The principal investigator will keep a link that identifies you and your coded
information. This link will be kept secure and available only to the principal
investigator, or selected members of the research team. Any information that can
identify you will remain confidential. Information will be kept confidential by using
only identification numbers on study forms, storing signed forms in locked cabinets,
and password protecting data stored on a computer. The research team will only give
this coded information to others to carry out this research study. The link to your
personal information will be kept for five years. After five years, the link will be
destroyed, and the data will become anonymous. The data will be kept in this
anonymous form indefinitely.
The information about your health that will be collected in this study includes:
•
•
•

Research study records
Records about phone calls made as part of this research
Records about your study visits
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Information about your health, which might identify your child, may be used or given
to:
•
•

•
•
•
•

The U.S. Department of Health and Human Services (DHHS) agencies
Representatives from Yale University, the Yale Human Research Protection
Program, and the Yale Human Investigation Committee (the committee that
reviews, approves, and monitors research on human subjects), who are
responsible for ensuring research compliance. These individuals are required
to keep all information confidential.
Those individuals at Yale who are responsible for the financial oversight of
research, including billings and payments.
The Principal Investigator, Dr. Matthew Grant
Co-Investigators and other investigators
Study Coordinator and members of the research team

By signing this form, you authorize the use and/or disclosure of the information
described above for this research study. The purpose for the uses and disclosures you
are authorizing is to ensure that the information relating to this research is available to
all parties who many need it for research purposes.
All healthcare providers subject to the Health Insurance Portability and
Accountability Act (HIPAA) are required to protect the privacy of your information.
The research staff at the Yale School of Medicine are required to comply with HIPAA
and to ensure the confidentiality of you or your child’s information.
If you choose to participate in this study, the investigators will check your electronic
medical record at Yale via EPIC to make sure you qualify. Any access to your
electronic medical record will be done consistent with HIPAA regulations.
Some of the individuals or agencies listed above may not be subject to HIPAA, and
therefore, may not be required to provide the same confidentiality protection. They
could use or disclose your information in ways not mentioned in this form. However,
to better protect your health information, agreements are in place with these
individuals and/or companies that require that they keep your information
confidential.
You have the right to review and copy your health information in your medical record
in accordance with institutional medical records policies. This authorization to use
and disclose your health information collected during your participation in this study
will never expire.

Voluntary Participation and Withdrawal
You are free to choose not to participate in this study. Your healthcare outside the
study, the payment for your healthcare, and your healthcare benefits will not be
affected if you do not agree to participate. However, you will not be able to enrol in
this research study and will not receive study procedures as a study participant if you
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do not allow use of your information as part of this study. You do not give up any of
your legal rights by signing this form.

Withdrawing from the Study
If you do not become a subject, you are free to stop and withdraw from this study at
any time during its course.
To withdraw from the study, you can call a member of the research time at any time
and tell him or her that you no longer wish to participate. This will cancel any future
appointments.
The researchers may withdraw you from participating in the research, if necessary.
This will only occur if you do not adhere to the assigned treatment.
If you choose not to participate, or if you withdraw, it will not harm your relationship
with your treatment team, or with the Yale School of Medicine and Yale New Haven
Hospital.

Withdrawing Your Authorization to Use and Disclose Your Health Information
You may withdraw or take away permission to use and disclose your health
information at any time. You do this by calling or sending written notice to the
Principal Investigator, Dr. Matthew Grant.
When you withdraw your permission, no new health information identifying you will
be gathered after that date. Information that has already been gathered may still be
used and given to others until the end of the research study, as necessary to ensure the
integrity of the study and/or study oversight.
You do not give up any of your legal rights by signing this form.

Questions
We have used technical and/or legal terms in this form. Please feel free to ask about
anything you do not understand and to consider this research and the permission form
carefully—as long as you feel necessary—before you make a decision.
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Authorization
I have read, or someone has read to me, this form and have decided to participate in
the project described above. Its general purpose, the specifics of my involvement,
possible hazards, and possible inconveniences have been explained to my satisfaction.
My signature indicates that I, ____________________, have received a copy of this
consent form.
Name of Subject: ____________________
Signature: __________________________
Relationship: _______________________
Date: _____________________________

__________________________________

____________________

Signature of Person Obtaining Consent

Date

If you have any further questions about this project, or if you have a research-related
problem, you may contact the Principal Investigator, Dr. Matthew Grant at (xxx) xxxxxxx.
After signing this form, if you have any questions about your privacy rights, please
contact the Yale Privacy Officer at (xxx) xxx-xxxx. If you would like to talk to
someone other than the researchers to discuss problems, concerns, and/or questions
you may have regarding the research, or to discuss your rights as a research subject,
you may contact the Yale Human Investigator Committee at (xxx) xxx-xxxx.
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Appendix C. Sample Size Calculation
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